Abstract
The initial research questions posed by the scientists faced with SARS-CoV-2 outbreaks were focused
on documenting the clinical presentation and the characteristics of the spread of the SARS-CoV-2 virus among CYP [1-3], and the optimal ways to diagnose CYP and treat those in need [1,4]. It quickly
became apparent that younger age groups have a considerably milder clinical presentation, but also that they
can very rarely develop a considerably more serious Multisystem Inflammatory Syndrome in Children (MISC) [1]. A special interest arose in how best to protect those particularly vulnerable. In this Editorial, we discuss
the development of scientific evidence related to those research questions in children and young people during
the first two years of the COVID-19 pandemic, based on the information available until December 1st, 2021.
on documenting the clinical presentation and the characteristics of the spread of the SARS-CoV-2 virus among CYP [1-3], and the optimal ways to diagnose CYP and treat those in need [1,4]. It quickly
became apparent that younger age groups have a considerably milder clinical presentation, but also that they
can very rarely develop a considerably more serious Multisystem Inflammatory Syndrome in Children (MISC) [1]. A special interest arose in how best to protect those particularly vulnerable. In this Editorial, we discuss
the development of scientific evidence related to those research questions in children and young people during
the first two years of the COVID-19 pandemic, based on the information available until December 1st, 2021.
Original language | English |
---|---|
Pages (from-to) | 01010 |
Journal | Journal of Global Health |
Volume | 11 |
DOIs | |
Publication status | Published - 25 Dec 2021 |
Externally published | Yes |